Insider Selling: Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) CEO Sells $3,091,571.40 in Stock

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) CEO Emil D. Kakkis sold 73,434 shares of the firm’s stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $42.10, for a total transaction of $3,091,571.40. Following the transaction, the chief executive officer now directly owns 641,731 shares of the company’s stock, valued at $27,016,875.10. This represents a 10.27 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website.

Ultragenyx Pharmaceutical Price Performance

Shares of NASDAQ:RARE opened at $40.02 on Friday. The business’s 50 day moving average price is $42.75 and its 200-day moving average price is $48.89. Ultragenyx Pharmaceutical Inc. has a 1 year low of $37.02 and a 1 year high of $60.37. The firm has a market capitalization of $3.70 billion, a price-to-earnings ratio of -6.31 and a beta of 0.60.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last posted its quarterly earnings data on Thursday, February 13th. The biopharmaceutical company reported ($1.39) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.32) by ($0.07). The company had revenue of $164.88 million for the quarter, compared to analysts’ expectations of $163.23 million. Ultragenyx Pharmaceutical had a negative net margin of 101.60% and a negative return on equity of 193.80%. On average, sell-side analysts expect that Ultragenyx Pharmaceutical Inc. will post -5.18 earnings per share for the current year.

Analyst Ratings Changes

A number of research firms have recently weighed in on RARE. Wells Fargo & Company increased their price objective on shares of Ultragenyx Pharmaceutical from $75.00 to $88.00 and gave the stock an “overweight” rating in a research note on Friday, December 20th. Piper Sandler increased their price target on Ultragenyx Pharmaceutical from $135.00 to $140.00 and gave the stock an “overweight” rating in a research report on Monday, January 13th. JPMorgan Chase & Co. decreased their price objective on Ultragenyx Pharmaceutical from $105.00 to $102.00 and set an “overweight” rating for the company in a report on Thursday, November 21st. HC Wainwright reaffirmed a “buy” rating and set a $95.00 target price on shares of Ultragenyx Pharmaceutical in a report on Friday, February 14th. Finally, Cantor Fitzgerald reiterated an “overweight” rating and set a $118.00 price target on shares of Ultragenyx Pharmaceutical in a research report on Wednesday, February 26th. One analyst has rated the stock with a hold rating and thirteen have given a buy rating to the stock. According to MarketBeat.com, Ultragenyx Pharmaceutical currently has an average rating of “Moderate Buy” and a consensus price target of $93.50.

Institutional Investors Weigh In On Ultragenyx Pharmaceutical

Large investors have recently bought and sold shares of the company. International Assets Investment Management LLC lifted its position in shares of Ultragenyx Pharmaceutical by 29,580.0% in the third quarter. International Assets Investment Management LLC now owns 10,388 shares of the biopharmaceutical company’s stock valued at $577,000 after acquiring an additional 10,353 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its holdings in Ultragenyx Pharmaceutical by 34.3% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,333 shares of the biopharmaceutical company’s stock valued at $181,000 after purchasing an additional 851 shares in the last quarter. Wealth Enhancement Advisory Services LLC lifted its holdings in Ultragenyx Pharmaceutical by 195.6% in the 3rd quarter. Wealth Enhancement Advisory Services LLC now owns 21,753 shares of the biopharmaceutical company’s stock valued at $1,208,000 after purchasing an additional 14,394 shares in the last quarter. Principal Financial Group Inc. boosted its stake in Ultragenyx Pharmaceutical by 740.0% during the 3rd quarter. Principal Financial Group Inc. now owns 86,440 shares of the biopharmaceutical company’s stock worth $4,802,000 after purchasing an additional 76,150 shares during the last quarter. Finally, Capital Performance Advisors LLP purchased a new stake in shares of Ultragenyx Pharmaceutical during the third quarter worth $107,000. 97.67% of the stock is currently owned by hedge funds and other institutional investors.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.